Rog is a Hindi noun meaning ‘disease’. The addition of the prefix ‘a’ changes its meaning to ‘without disease’, a fitting name for our company aiming to bring cures for cancers with a high unmet need.
AROG is a privately held, late-stage biopharmaceutical company. At AROG we are focused on developing treatments for people with rare cancers.
AROG is based in Dallas, Texas, and was founded on March 29, 2010. We base our approach on two principles: improving the lives of cancer patients and focusing on indications with high unmet need.
AROG obtained exclusive worldwide rights to several patented benzimidazole-based compounds from Pfizer in April 2010. AROG has conducted several clinical trials with crenolanib in acute myeloid leukemia with FLT3 mutations in newly diagnosed or relapsed/refractory (R/R) patient populations; as well as a variety of solid tumors including R/R gastric cancer, gastrointestinal stromal tumors (GIST), and glioblastoma.
To date, AROG has evaluated crenolanib across 16 Phase I-III trials in hundreds of patients.
We have assembled an experienced and talented group of leaders to execute our vision.
The most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target.
Our Recent Publications
Goldberg, A., et al., Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib […]
Zhang H, Savage S, Schultz AR, et al. Clinical resistance to crenolanib in acute […]
Blay J-Y, Heinrich MC, Hohenberger P, et al. A randomized, double-blind, placebo-controlled, phase III […]
Arog Pharmaceuticals Receives FDA Orphan Drug Designation for Crenolanib for the Treatment of Gastric […]